原发性甲状腺淋巴瘤21例临床分析

Clinical Analysis of 21Cases of Primary Thyroid Malignant Lymphoma

探讨原发性甲状腺淋巴瘤(PTL)的临床特点、治疗及预后。回顾性分析2009年9月2017年6月就诊于大连医科大学附属第二医院的21例PTL患者的临床资料。21例患者均表现为颈部迅速增大的肿物,12例患者伴有明显的压迫症状。其中,弥漫性大B细胞淋巴瘤(DLBCL)14例,黏膜相关组织淋巴瘤(MALT)4例,滤泡型淋巴瘤(FL)3例。依据Ann Arbor分期,ⅠE期12例,ⅡE期9例。结果显示,DLBCL患者2年、5年生存率(OS)分别为83.6%、55.7%,MALT及FL患者2年、5年生存率均为100.0%,后者预后优于前者,但差异无统计学意义(P=0.151)。ⅠE期患者2年、5年生存率均为100.0%,ⅡE期患者2年、5年生存率分别为71.1%、47.4%,差异有统计学意义(P=0.037)。

To evaluate the clinical characteristics,diagnosis and treatment outcomes of primary thyroid lymphoma(PTL).Authors presented 21 patients with PTL treated from September 2009 to June 2017 in the Second Affiliated Hospital of Dalian Medical University.21 patients showed a rapidly growing thyroid mass,and 12 patients with significant compressive symptoms.14 patients had diffused large B-cell lymphoma(DLBCL),4 patients had mucosa-associated lymphoma tissue(MALT),and 3 patients had follicular lymphoma(FL).There were 12 patients with stageⅠE and 9 patients with stageⅡE.The 2-year and 5-year overall survival(OS)of patients with DLBCL were 83.6%and 55.7%respectively,compared with 100.0%and 100.0%in MALT and FL patients,which showed no significant difference(P=0.151).The 2-year and 5-year OS were 100.0% and 100.0% in patients with stageⅠE and 71.1%,47.4%respectively in patients with stageⅡE(P=0.037),which showed significant difference.